Bladder cancer trials in Germany

In Germany 38 Also abroad 630

28 of 38 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Where
Herne
Age
18 years and over
People
240 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07475806
Phase 3Not yet taking people in Germany
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
Where
Bonn, Magdeburg, Mannheim
Age
18 years and over
People
203 worldwide
Run by
Systimmune Inc.
See details and how to join2026-527617-29-00
Phase 3Taking people
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Where
Berlin, Dresden, Duesseldorf, Hamburg, Heidelberg, Herne, Muenster, Regensburg, Stuttgart, Ulm
Age
18 years and over
People
590 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07419295 · EU 2024-520014-22-00
Phase 1Taking people
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Where
Bonn, München, Tübingen
Age
18 years and over
People
677 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05614739 · EU 2022-502755-59-00
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Where
Berlin, Braunschweig, Cologne, Dresden, Frankfurt am Main, Hamburg, Herne, Jena, München, Straubing, Stuttgart
Age
18 years and over
People
641 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06319820
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Where
Cologne, Herne, Leverkusen, Mannheim, Nuertingen, Regensburg
Age
18 years and over
People
220 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06919965 · EU 2024-519493-39-00
Phase 2/3Taking people
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
Where
Aachen, Cologne, Dresden, Essen, Goettingen, Halle Saale, Hamburg, Herne, Jena, Kiel, Luebeck, Lutherstadt Eisleben, Mannheim, Munich, Nuertingen, Stuttgart, Tuebingen, Ulm
Age
18 years and over
People
343 worldwide
Run by
Daiichi Sankyo Inc.
See details and how to join2024-516906-47-00
Phase 3Not yet taking people in Germany
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Where
Dresden, Duesseldorf, Hamburg, Heidelberg, Herne, Jena, Luebeck, Muenster, Ulm
Age
18 years and over
People
390 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566156 · EU 2026-525612-34-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Frankfurt
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1Taking people
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Cologne, Essen
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00
Phase 1/2Taking people
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Where
Bochum, München, Ulm
Age
18 years and over
People
245 worldwide
Run by
BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00
Phase 3Not yet taking people in Germany
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Where
Bad Saarow, Bielefeld, Bonn, Cologne, Dresden, Duisburg, Düsseldorf, Erlangen, Essen, Frankfurt, Freiburg im Breisgau, Greifswald, Hamburg, Heidelberg, Homburg, Koblenz, Lübeck, Munich, Münster, Nuremberg, Nürtingen, Rostock, Tübingen, Ulm, Würzburg
Age
18 years and over
People
450 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218380 · EU 2025-522855-25-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Essen, Heidelberg, Herne, Jena, Nuertingen, Tuebingen
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 2Taking people
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Where
Halle Saale, Herne, Jena, Munich, Stuttgart
Age
18 years and over
People
308 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06833073 · EU 2024-517335-46-00
Phase 3Taking people
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.
Where
Bochum, Bonn, Dresden, Duisburg, Frankfurt am Main, Giessen, Hamburg, Hanover, Herne, Magdeburg, Mannheim, Mettmann, Muenster, Nuertingen, Nuremberg, Regensburg, Rostock, Stuttgart, Tuebingen, Ulm
Age
18 years to 64 years
People
262 worldwide
Run by
AstraZeneca AB
See details and how to join2025-525030-57-00
Phase 2Taking people
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
Where
Berlin, Dresden, Duesseldorf, Gera, Goettingen, Herne, Luebeck, Muenster, Munich, Potsdam, Regensburg, Stuttgart
Age
18 years and over
People
88 worldwide
Run by
Astellas Pharma Global Development Inc.
See details and how to join2025-524488-18-00
Phase 3Taking people
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Where
Guetersloh, Muenster, Oldenburg
Age
18 years and over
People
87 worldwide
Run by
Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00
Phase 2/3Taking people
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Where
Eisleben Lutherstadt, Herne, Nürtingen, Stuttgart
Age
18 years and over
People
630 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07129993
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Dresden, Essen, Frankfurt, Ulm, Würzburg
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
No phaseNot yet taking people in Germany
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors
Where
Augsburg, Erlangen, Munich, Nuremberg
Age
18 years and over
People
75 worldwide
Run by
Ludwig-Maximilians - University of Munich
See details and how to joinNCT07762820
Phase 1/2Taking people
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Where
Cologne, Duisburg, Erlangen, Mettmann, Nuertingen, Regensburg, Tuebingen
Age
18 years and over
People
350 worldwide
Run by
enGene, Inc.
See details and how to joinNCT04752722 · EU 2024-512900-20-00
Phase 2/3Taking people
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Where
Berlin, Düsseldorf, Frankfurt, Hamburg, Hanover, Heidelberg, Herne, Jena, Kiel, Munich, Nuremberg, Nürtingen, Regensburg, Ulm
Age
18 years and over
People
470 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07106762
Phase 2Taking people
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Where
Berlin, Frankfurt am Main, Heidelberg
Age
8 years and over
People
254 worldwide
Run by
Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00
Phase 3Not yet taking people in Germany
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Where
Bochum, Bonn, Dresden, Duisburg, Frankfurt am Main, Hamburg, Hanover, Herne, Magdeburg, Mannheim, Marburg, Mettmann, Münster, Nuremberg, Nürtingen, Regensburg, Rostock, Stuttgart, Tübingen, Ulm
Age
18 years and over
People
915 worldwide
Run by
AstraZeneca
See details and how to joinNCT07720284